- Home
- QSI vs CCCC Comparison
QSI vs CCCC Comparison
Compare QSI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | CCCC |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 240.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QSI | CCCC |
|---|---|---|
| Price | $1.26 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.88 | ★ $7.25 |
| AVG Volume (30 Days) | ★ 4.2M | 1.9M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,177,000.00 | ★ $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $159.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.20 | N/A |
| 52 Week Low | $0.95 | $1.09 |
| 52 Week High | $5.77 | $4.26 |
Technical Indicators
Market Signals| Indicator | QSI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 34.93 |
| Support Level | $1.18 | $2.00 |
| Resistance Level | $1.31 | $2.69 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 20.83 | 5.92 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.